HAZLET, N.J. - s4story -- In this symposium, ATTR experts will describe strategies for improving recognition of clinical clues for ATTR-CM and for making an earlier and accurate diagnosis. Evidence with disease-modifying therapies for ATTRCM will be presented including interpretations of recently completed clinical trials. Most effective use of HF medications in ATTR-CM patients will also be discussed. Two cases with panel discussions will be presented, 1) avoiding pitfalls and explaining best practices to overcome management challenges, and 2) successfully addressing the complexities of diagnosing hereditary ATTR-CM and recognizing the importance of genetic testing not only for the index patient but also for identifying at-risk family members and initiating evidence-based interventions.

Click here for more information

More on S For Story

• Claude Zdanow named Managing Director in Miami, Florida
• Birch Tree Publishing Launches as Independent Publishing Imprint
• Pharmacist Flo Launches New Children's Book, "Pharmacist Flo's Halloween Adventure"
• Pregis Launches Sharp InfinX: On-Demand Rightsized Mailing System Delivering a Precision-Sized Mailer for Every Order
• New Book Release - The Legend in the Stone

CHAIR

Mathew Maurer, MD
Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center
Vagelos College of Physicians & Surgeons
New York, New York

FACULTY

Sarah Cuddy, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Justin Grodin, MD, MPH
Associate Professor of Medicine
Department of Internal Medicine – Division of Cardiology
University of Texas Southwestern Medical Center
Dallas, Texas

Ahmad Masri, MD, MS
Associate Professor of Medicine
Oregon Health & Science University
Portland, Oregon

Educational Objectives

• Identify suggestive findings for ATTR-CM
• Summarize the diagnostic evaluation for cardiac amyloidosis
• Interpret the evidence for ATTR-CM disease-modifying therapies
• Discuss strategies for the use of HF medications in patients diagnosed with ATTR-CM
• Explain the importance of genetic testing in the diagnosis of ATTR-CM
• Describe the challenges associated with the management of transthyretin amyloidosis

Target Audience

More on S For Story

• netElastic Announces vBNG And CGNAT 2.0 General Availability
• Shadow of a Survivor: This Astonishing Memoir - From One of the World's Longest Cancer Survivors
• Award-Winning Author Robert L. Cauley Relaunches Hit Sci-Fi Series Under New Imprint
• Adapters By Felipe Veit Helps Professionals Turn Experience Into an Advantage in the Age of AI
• Joel Rodriguez Tirado Releases Grandpa's Toolbox: The Tools You Need to Build a Great Life

This educational activity is intended for cardiovascular clinicians.

Educational Grant

Voxmedia gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals LP and Ionis Pharmaceuticals.

Accreditation and Credit Designation Statements

Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Voxmedia, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.